share_log

富邦股份(300387.SZ):上半年深耕现代生物领域,并购康欣生物与湘渝生物,在产品研发等实现营业收入1.1亿元

Hubei Forbon Technology (300387.SZ): In the first half of the year, it focused on developing the modern biotechnology field, acquired Kangxin Biology and Xiangyu Biology, and achieved revenue of 0.11 billion yuan in product research and development.

Gelonghui Finance ·  Oct 16 21:06

Grelon October 16th Hubei Forbon Technology (300387.SZ) stated in investor relations that the company relies on Kangxin Biology and Xiangyu Biology, the two main carriers, national biobased pesticide engineering technology research center, China Agricultural University and other scientific research platforms, actively launched green and efficient microbial agents, biofertilizers, biopesticides, nitrogen-fixing legumes, biotechnology. New generation of agricultural products such as food additives. In the first half of 2024, the company delved into the modern biotechnology field, deepening the industry chain, innovation chain, and value chain through the acquisition of Kangxin Biology and Xiangyu Biology, continuously refining product research and development and application scenarios, advancing marketing team construction, brand value transmission, and orderly achieving a revenue of 109.6267 million yuan.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment